Twitxy Saved

Marcus Goncalves

Verified account This account is verified. Learn more

@MarcusDGon

MD/PhD Endocrinologist Scientist. Cancer metabolism, cachexia, insulin, PI3K, diabetes, obesity. GI Villi lover. Metabolic Consulting. NYJ/NYY/NYCFC/NYK fan.
New York goncalveslab.com Joined April 2009
774 Following 2.9K Followers 7K Posts

Latest posts 5

Marcus Goncalves Verified account @MarcusDGon
Resistance exercise on tirzepatide: 3 supervised sessions a week for 40 weeks bought back 1.1 kg of lean mass, about 23% of the loss. Lean mass still fell 3.6 kg. Real-world adherence will be far below 91% and no reimbursement for hosting these sessions. Effort versus payoff. nature.com/articles/s4159…
www.nature.com Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomi... Nature Medicine - Participants undergoing resistance exercise while receiving tirzepatide lost less lean mass than participants receiving tirzepatide alone.
1 replies 4 reposts 8 likes 1.3K views View on X
Marcus Goncalves Verified account @MarcusDGon
Congratulations to Faeth and @GOG investigators on PIK-201. Serabelisib + sapanisertib + paclitaxel in PAM-mutant endometrioid endometrial cancer, 98% post-IO: ORR 33%, mPFS 7.4 mo. Chemo alone in this setting: ORR ~15-17%, mPFS 3.8-3.9 mo. Roughly 2x on both. $FTH investors.faeththerapeutics.com/news-releases/…
investors.faeththerapeutics.com Faeth Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 Trial Evaluating PIKTOR... Confirmed Objective Response Rate (ORR) of 33% in efficacy-evaluable patients (12 of 36), and a disease control rate (DCR) of 83% Among patients with a PIK3CA mutation, the confirmed ORR was 44% (7...
1 replies 0 reposts 12 likes 1.3K views View on X